Orchid Pharma new antibiotic drug gets EMA approval; stock surges 20% ‘Exblifep’ obtained marketing authorisation from the EMA for the treatment of complex urinary tract infections, pneumonia, and bacteremia caused by ESBL-producing pathogens. By fortuneindia.com
